Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Bayer Aktienges ADR (BAYRY)

Bayer Aktienges ADR (BAYRY)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
6.4300 +0.1800 (+2.88%) 04/24/25 [OTC US]
N/A x N/A N/A x N/A
Post-market 6.4300 unch (unch) 15:59 ET
News & Headlines for Thu, Apr 24th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS Study

Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus (ocrelizumab).The company announced that a phase III study, MUSETTE, which compared...

BAYRY : 6.4300 (+2.88%)
GILD : 106.15 (-0.22%)
REGN : 599.76 (+2.03%)
RHHBY : 39.7500 (+1.56%)
FDA Grants Accelerated Approval to NVS Kidney Disease Drug

Novartis NVS obtains FDA approval of atrasentan, a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN)...

BAYRY : 6.4300 (+2.88%)
NVS : 111.17 (+0.94%)
GILD : 106.15 (-0.22%)
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States

Sanofi SNY and partner, Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia (fitusiran) as the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce...

BAYRY : 6.4300 (+2.88%)
CORT : 71.79 (+3.64%)
ALNY : 242.61 (+0.26%)
SNY : 53.54 (+0.98%)
J&J's Third Bankruptcy Attempt to End Talc Suits Rejected

Johnson & Johnson JNJ announced that a bankruptcy court in Texas has rejected its bankruptcy plan to resolve talc lawsuits for the third time.J&J faces more than 62,000 lawsuits for its talc-based products,...

BAYRY : 6.4300 (+2.88%)
JNJ : 154.93 (-0.29%)
GILD : 106.15 (-0.22%)
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib).The regulatory body approved Cabometyx for the treatment of adult and pediatric patients...

BAYRY : 6.4300 (+2.88%)
NVO : 62.63 (+2.17%)
EXEL : 37.21 (+1.17%)
BMY : 48.69 (+0.33%)
Bayer Enters License Agreement With China’s Puhe BioPharma For Cancer Drug Candidate: Retail Stays Bullish

Bayer’s Pharmaceuticals Division’s Head of Business Development and Licensing Juergen Eckhardt said the drug’s “highly selective targeting” of cancer cells while sparing healthy ones is “very...

BAYRY : 6.4300 (+2.88%)
Bayer Down on Verdict to Pay $2.1B to Plaintiff in Roundup Litigation

Shares of pharma conglomerate Bayer BAYRY were down 7.1% on March 24, following a setback in the ongoing Roundup Litigation.Bayer reported that, on March 21, the jury at the Barnes Roundup trial in the...

BAYRY : 6.4300 (+2.88%)
NVO : 62.63 (+2.17%)
GILD : 106.15 (-0.22%)
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%

Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This update allows cash-paying patients or those with commercial insurance, which does...

BAYRY : 6.4300 (+2.88%)
NVO : 62.63 (+2.17%)
LLY : 859.73 (+3.65%)
GILD : 106.15 (-0.22%)
5 Large Drug Stocks to Watch as Industry Recovers

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due to the better-than-expected fourth-quarter performance of large drugmakers and...

BAYRY : 6.4300 (+2.88%)
NVO : 62.63 (+2.17%)
NVS : 111.17 (+0.94%)
ABBV : 180.37 (+1.88%)
PFE : 22.78 (+1.74%)
FDA Approves Novartis Drug for Rare Kidney Disease Treatment

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication.The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to reduce proteinuria.C3G...

BAYRY : 6.4300 (+2.88%)
NVS : 111.17 (+0.94%)
GILD : 106.15 (-0.22%)

Barchart Exclusives

1 ‘Strong Buy’ Dividend Stock to Buy for an ‘America First’ World
GE Aerospace is emerging as a top “Strong Buy” dividend stock, with an 11% jump in revenue and a nearly $1 billion investment in U.S. manufacturing. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective